A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia.
Gautam BorthakurOlatoyosi OdenikeIbrahim AldossDavid A RizzieriThomas PrebetChris ChenRelja PopovicDimple A ModiRujuta H JoshiJohannes E WolffBrian A JonasPublished in: Cancer (2021)
Mivebresib is a novel drug that influences the way cancer cells read genetic information. Mivebresib was tested together with venetoclax in patients with acute myeloid leukemia after standard medicines failed and the disease returned, or when standard medicine was unavailable. Adverse effects were described for different drug doses, and the dose that is tolerable was determined. In some patients, their leukemia improved for some time. More studies are necessary to determine whether mivebresib can be used to treat acute myeloid leukemia.
Keyphrases
- acute myeloid leukemia
- allogeneic hematopoietic stem cell transplantation
- end stage renal disease
- newly diagnosed
- ejection fraction
- prognostic factors
- chronic kidney disease
- chronic lymphocytic leukemia
- randomized controlled trial
- emergency department
- open label
- drug induced
- patient reported outcomes
- single molecule
- adverse drug
- acute lymphoblastic leukemia
- health information